Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 19 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 10159727

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted

  2. US 10154970

    Methods for immunomodulation of cancer and infectious disease therapy

    The Regents of the University of California · Granted Dec 18, 2018 · Expires Dec 13, 2038

    granted

  3. US 10143751

    Photodynamic therapy, formulation usable for this purpose, and method for the production and use thereof

    SANOCHEMIA PHARMAZEUTIKA AG · Granted Dec 4, 2018 · Expires Nov 29, 2038

    granted

  4. US 10137104

    Combination therapy with an anti-hyaluronan agent and therapeutic agent

    HALOZYME, INC. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted

  5. US 10130651

    RNAi Therapy for Hepatitis B Virus Infection

    Arrowhead Pharmaceuticals, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  6. US 10130659

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  7. US 10130658

    Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

    Provectus Pharmatech, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  8. US 2018326059

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS AG [DE] · Granted Nov 15, 2018 · Expires Nov 10, 2038

    granted

  9. US 10117915

    Modulation of yeast-based immunotherapy products and responses

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted

  10. US 10087232

    Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

    Protalix Ltd. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted

  11. US 10081669

    Therapy for filovirus infection

    The United States of America as represented by the Secretary of the Army · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted

  12. US 10072084

    Dual specific immunotoxin for brain tumor therapy

    The United States of America as Represented by the Secretary Department of Health and Human Services (NIH) · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted

  13. US 10046057

    Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy

    The Regents of the University of California · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  14. US 10036751

    Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and method of prognosticating survival rate in glioblastoma mulztiforme patient after treatment

    China Medical University Hospital · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted

  15. US 10023916

    Markers of tumor cell response to anti-cancer therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  16. US 10023637

    Combination immunotherapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  17. US 9987241

    Enzyme conjugate and prodrug cancer therapy

    The Board of Regents of the University of Oklahoma · Granted Jun 5, 2018 · Expires May 31, 2038

    granted

  18. US 9980961

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted

  19. US 9975959

    Administration of kynurenine depleting enzymes for tumor therapy

    The Board of Regents of the University of Texas System · Granted May 22, 2018 · Expires May 17, 2038

    granted

  20. US 9974800

    Therapy for inhibition of single-stranded RNA virus replication

    RedHill Biopharma Ltd. · Granted May 22, 2018 · Expires May 17, 2038

    granted

  21. US 9952216

    Brain-specific enhancers for cell-based therapy

    The Regents of the University of California · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted

  22. US 9937192

    Combination therapy to treat mycobacterium diseases

    SPERO TRINEM, INC. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted

  23. US 9926380

    Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

    The Board of Regents of the University of Texas System · Granted Mar 27, 2018 · Expires Mar 22, 2038

    granted

  24. US 9920297

    Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1

    Vaximm AG · Granted Mar 20, 2018 · Expires Mar 15, 2038

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.